Application Number	Application/Control No.	Reexamination	
	1.4.11		NOTAL
Document Code - DISQ	linternal L	Document – DC 	NOIWAIL

TERMINAL DISCLAIMER	⊠ APPROVED	☐ DISAPPROVED
Date Filed : 5/17/2005	This patent is subject to a Terminal Disclaimer	

Approved/Disapproved by:		

U.S. Patent and Trademark Office



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Bart De Corte, et al. Confirmation No.: 5916

Application No.: 10/649,017 Group Art Unit: 1624

Examiner: Balasubramanian,

Filing Date: August 27, 2003

Venkataraman

For: 2,4-DISUBSTITUTED TRIAZINE DERIVATIVES

## TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING REJECTION OVER A PRIOR PATENT

The owner, Janssen Pharmaceutica, N.V., of 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173, as presently shortened by any terminal disclaimer, of prior Patent No. 6,638,932. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of the prior patent, as presently shortened by any terminal disclaimer, in the event that it: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, the state of the full st

05/19/2005 SHINASS1 00000019 10649017